| Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy G Randon, G Maddalena, MM Germani, CC Pircher, P Manca, F Bergamo, ... JCO Precision Oncology 6, e2200037, 2022 | 17 | 2022 |
| Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer C Antoniotti, F Marmorino, A Boccaccino, S Martini, M Antista, D Rossini, ... European Journal of Cancer 165, 116-124, 2022 | 8 | 2022 |
| Transcriptomic signatures of MSI-high metastatic colorectal cancer predict efficacy of immune checkpoint inhibitors C Gallois, M Landi, J Taieb, M Sroussi, B Saberzadeh-Ardestani, ... Clinical Cancer Research 29 (18), 3771-3778, 2023 | 2 | 2023 |
| Colorectal neoplastic emergencies in immunocompromised patients: preliminary result from the Web-based International Register of Emergency Surgery and Trauma (WIRES-T trial) F Coccolini, A Mazzoni, C Cremonini, L Cobuccio, M Pucciarelli, G Vetere, ... Updates in Surgery 75 (6), 1579-1587, 2023 | 2 | 2023 |
| Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a … E Dell’Aquila, D Rossini, CAM Fulgenzi, A Passardi, E Tamburini, ... ESMO open 7 (6), 100606, 2022 | 2 | 2022 |
| 367P Prospective evaluation of emergent RAS and BRAF mutations in pre-treated metastatic colorectal cancer patients candidate to anti-EGFR re-treatment: Preliminary findings … MM Germani, D Rossini, G Vetere, M Giordano, I Capone, P Manca, ... Annals of Oncology 33, S704, 2022 | 2 | 2022 |
| Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated … R Moretto, MM Germani, J Ros, F Daniel, F Ghelardi, G Vetere, ... JCO Precision Oncology 7, e2300255, 2023 | 1 | 2023 |
| The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study F Marmorino, L Faggioni, D Rossini, M Gabelloni, A Goddi, L Ferrer, ... Future Oncology 19 (23), 1601-1611, 2023 | 1 | 2023 |
| FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases C Antoniotti, G Vetere, C Cremolini Annals of Translational Medicine 10 (18), 2022 | 1 | 2022 |
| Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer S Hedayat, L Cascione, D Cunningham, M Schirripa, A Lampis, JC Hahne, ... Clinical Cancer Research, OF1-OF20, 2024 | | 2024 |
| Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset MM Germani, G Vetere, F Santamaria, R Intini, F Ghelardi, M Bensi, ... ESMO open 9 (4), 102996, 2024 | | 2024 |
| Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial MM Germani, G Vetere, M Giordano, P Ciracì, I Capone, E Tamborini, ... Frontiers in Oncology 13, 1307545, 2024 | | 2024 |
| Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies V Fanotto, D Rossini, M Casagrande, F Bergamo, A Spagnoletti, D Santini, ... Cancers 15 (22), 5451, 2023 | | 2023 |
| 571P Artificial intelligence-powered analysis of tumor lymphocytes infiltration: A translational analysis of AtezoTRIBE trial M Carullo, C Antoniotti, C Ahn, T Lee, V Angerilli, M Ambrosini, D Rossini, ... Annals of Oncology 34, S421, 2023 | | 2023 |
| P-90 Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving … G Vetere, M Germani, M Bensi, C Antoniotti, S Lonardi, A Passardi, ... Annals of Oncology 34, S45, 2023 | | 2023 |
| SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or … M Germani, R Moretto, J Ros, R Intini, F Ghelardi, G Vetere, R Toledo, ... Annals of Oncology 34, S176, 2023 | | 2023 |
| Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAF V600E mutated (mut) metastatic colorectal cancer (mCRC) receiving … G Vetere, MM Germani, M Bensi, C Antoniotti, S Lonardi, A Passardi, ... Journal of Clinical Oncology 41 (16_suppl), 3568-3568, 2023 | | 2023 |
| Predictive impact of RNF43 mutation (mut) in patients (pts) with pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with target therapy … MM Germani, R Moretto, J Ros Montañá, R Intini, F Ghelardi, G Vetere, ... Journal of Clinical Oncology 41 (16_suppl), 3569-3569, 2023 | | 2023 |
| Negative ultra-selection of patients with RAS/BRAF wild-type (wt), microsatellite stable (MSS) metastatic colorectal cancer (mCRC) receiving anti-EGFR-based … G Randon, G Maddalena, MM Germani, F Pagani, F Bergamo, ... Cancer Research 82 (12_Supplement), 1269-1269, 2022 | | 2022 |
| Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors MMG Martinetti, C Boccaccio, G Vetere, S Mouillet-Richard, A de Reynies, ... | | |
